Compare ENOV & ANAB Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | ENOV | ANAB |
|---|---|---|
| Founded | 1995 | 2005 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Fluid Controls | Biotechnology: Pharmaceutical Preparations |
| Sector | Industrials | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 1.5B | 1.6B |
| IPO Year | 2008 | 2015 |
| Metric | ENOV | ANAB |
|---|---|---|
| Price | $23.87 | $57.66 |
| Analyst Decision | Strong Buy | Buy |
| Analyst Count | 9 | 12 |
| Target Price | $47.38 | ★ $71.67 |
| AVG Volume (30 Days) | ★ 1.2M | 636.9K |
| Earning Date | 05-07-2026 | 05-08-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ 91.02 |
| EPS | ★ N/A | N/A |
| Revenue | N/A | ★ $234,603,000.00 |
| Revenue This Year | $6.36 | N/A |
| Revenue Next Year | $5.31 | $52.14 |
| P/E Ratio | ★ N/A | N/A |
| Revenue Growth | N/A | ★ 157.01 |
| 52 Week Low | $19.14 | $17.11 |
| 52 Week High | $34.28 | $73.30 |
| Indicator | ENOV | ANAB |
|---|---|---|
| Relative Strength Index (RSI) | 41.38 | 52.22 |
| Support Level | $21.02 | $53.46 |
| Resistance Level | $24.08 | $57.70 |
| Average True Range (ATR) | 1.50 | 2.45 |
| MACD | -0.78 | 0.60 |
| Stochastic Oscillator | 3.05 | 82.21 |
Enovis Corp is a medical technology manufacturer and distributor of medical devices used in reconstructive surgery, rehabilitation, pain management, and physical therapy. Its products support patient care from injury prevention through post-surgical or post-injury rehabilitation and treatment of degenerative conditions. The company's reportable segments include Prevention & Recovery and Reconstructive segments. The majority of revenueis derived from the Prevention & Recovery segment, which includes products that are used by orthopedic specialists, primary care physicians, physical therapists, chiropractors, athletic trainers and other healthcare professionals to treat patients with musculoskeletal conditions resulting from degenerative diseases, deformitiesand sports-related injuries.
AnaptysBio Inc is a clinical-stage biotechnology company. The company is focused on developing antibody product candidates for unmet medical needs in inflammation and immuno-oncology. The company is developing immune cell modulating antibodies, including two wholly owned checkpoint agonists in clinical-stage development, for autoimmune and inflammatory diseases; rosnilimab, PD-1 agonist in a Phase 2b trial for the treatment of moderate-to-severe rheumatoid arthritis (RA) and a Phase 2 trial for the treatment of moderate-to-severe ulcerative colitis (UC); and ANB032, BTLA agonist, in a Phase 2b trial for the treatment of moderate-to-severe atopic dermatitis (AD).